Stella Pharma Corporation

Tokyo Stock Exchange 4888.T

Stella Pharma Corporation Price to Sales Ratio (P/S) on January 14, 2025: 60.23

Stella Pharma Corporation Price to Sales Ratio (P/S) is 60.23 on January 14, 2025, a 11.89% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Stella Pharma Corporation 52-week high Price to Sales Ratio (P/S) is 75.63 on October 01, 2024, which is 25.57% above the current Price to Sales Ratio (P/S).
  • Stella Pharma Corporation 52-week low Price to Sales Ratio (P/S) is 43.35 on August 05, 2024, which is -28.03% below the current Price to Sales Ratio (P/S).
  • Stella Pharma Corporation average Price to Sales Ratio (P/S) for the last 52 weeks is 63.74.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Tokyo Stock Exchange: 4888.T

Stella Pharma Corporation

CEO Mr. Koki Uehara
IPO Date April 22, 2021
Location Japan
Headquarters ORIX Kouraibashi Building
Employees 44
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.

StockViz Staff

January 15, 2025

Any question? Send us an email